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Aim: The protective role of high-density lipoprotein (HDL) against atherosclerosis is well 
known. However, both structural and functional changes of the HDL particles may affect its 
protective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreased 
HDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Some 
changes in HDL subfraction distributions were also studied previously, but data on structural 
and functional changes in dyslipidemia are not complete. Therefore, the authors aimed to 
evaluate these qualitative and quantitative markers of HDL in dyslipidemic patients and 
healthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteins 
and MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patients 
and in 32 healthy gender-matched controls. Additionally, HDL subfractions were detected 
by an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantly 
higher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol, 
triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were found 
in patients compared to the healthy subjects. There were no significant differences in PON1 
paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratio 
was significantly higher in patients. There was a shift towards the smaller HDL subfractions, 
but only the intermediate HDL ratio was significantly lower in patients compared to controls. 
Conclusion: The results highlight the importance of HDL-associated pro- and antioxidant 
enzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm that 
quantification of HDL-C level alone provides limited data regarding HDL’s cardioprotective 
effect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia.
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INTRODUCTION
High-density lipoprotein (HDL) is a fraction of 
small, dense, protein-rich lipoprotein that is highly 
heterogeneous in their structural, chemical and 
biological properties. Using dif ferent analytical 
methods HDL can be separated to subclasses 
differing in size, density, shape and lipid and protein 
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composition[1]. Therefore, the subfraction distribution 
of HDL has implications for their functions. Although 
the compositional and functional heterogeneity of HDL 
particles is well known, HDL is often regarded as a 
single entity characterized by measurement of HDL-
cholesterol (HDL-C) levels. Previous epidemiological 
studies have clearly shown that levels of HDL-C are 
inversely associated with the risk of coronary artery 
disease and its thrombotic complications[2,3]. Over 
the last few decades, substantial progress has been 
made in understanding how the HDL particle exerts 
protective effects on the vessel wall. HDL and its 
main protein constituent, apolipoprotein A1 (ApoA1) 
is protective in processes involved in atherogenesis, 
including mediation of reverse cholesterol transport, 
protection against oxidative stress, and inhibition of 
cytokine-induced expression of cellular adhesion 
molecules on endothelial cells. However, under 
particular circumstances, HDL particles may become 
dysfunctional caused by the loss of antioxidant and 
anti-inflammatory proteins in combination with a 
gain of acute phase proteins and some further pro-
inflammatory components. This pro-inflammatory, 
dysfunctional HDL is unable to protect low-density 
lipoprotein (LDL) from oxidation and to prevent 
monocyte migration into the vessel wall induced by 
oxidized LDL particles [4]. Myeloperoxidase (MPO) 
mediates the oxidation of ApoA1 that creates a 
dysfunctional HDL particle, which activates nuclear 
factor kappa-B and promotes inflammation in the 
vessel wall [5]. MPO level and its role in oxidative 
stress and inflammation has been implicated in the 
pathophysiology of cardiovascular diseases such as 
coronary artery disease [6]. Human paraoxonase-1 
(PON1) is a calcium-dependent lactonase that 
is produced by the liver and almost exclusively 
associated with HDL [7]. Although hydrolysis of 
homocysteine thiolactone might represent a major 
physiologic function of PON1[8], several fur ther 
substrates have been described including other 
lactones[9], organophosphates and lipid peroxides[7]. 
Interestingly, some previous studies proved that PON1 
is predominantly associated to the smaller and denser 
HDL3 subfractions, and PON1 activity of HDL2 was 
only 4% of that in HDL3[10]. Furthermore, previous data 
indicate that MPO, PON1 and HDL from a functional 
ternary complex in which MPO and PON1 inhibit each 
other’s activity demonstrating the dysfunction of the 
HDL particle[11].
Dysl ip idemia character ized by high levels of 
t r ig lycer ide,  tota l  and LDL cholestero l  is  an 
established risk factor for coronary heart disease. 
Therefore, to reduce the risk of cardiovascular 
complications lipid lowering treatment is widely used 
in this patient population. Additionally, combined 
forms of hyperlipidemia often require combined drug 
therapy. At the same time, it must be noted that lipid 
lowering agents, such as statins [12,13], f ibrates [14] 
and ezetimibe [15] have a significant effect on HDL 
composition and function. Consequently, evaluating 
the effect of various lipid abnormalities on HDL 
properties in patients on lipid lowering therapy can be 
misleading[16].
Therefore, we investigated the structural and some 
functional HDL proper ties in newly diagnosed, 
untreated dyslipidemic patients and in healthy controls 
to evaluate the effect of dyslipidemia on the structural 
and functional properties of HDL characterized by the 
serum levels of HDL subfractions and MPO, PON1 
paraoxonase and arylesterase activities and PON1 
phenotyping. We hypothesized that the level and 
ratio of large HDL subfractions are higher, and the 
level and ratio smaller HDL subfractions are lower in 
dyslipidemic subjects compared to healthy controls. A 
lower number of smaller HDL subfractions may result 
in lower PON activities and higher MPO levels.
METHODS
Study population
The study protocol was approved by local and regional 
ethics committees and carried out in accordance 
with the Declaration of Helsinki of World Medical 
Association. All investigated subjects gave their written 
informed consent to participate in the study. We 
enrolled eighty-one newly diagnosed, untreated patient 
with Fredrickson type IIa and IIb hyperlipidemia that 
were referred to our lipid outpatient clinic at Department 
of Internal Medicine, University of Debrecen. Physical 
examination and carotid ultrasound were performed 
regularly. Further vascular imaging techniques (Doppler 
ultrasound and computer tomography) were performed 
in case of complaints or abnormal physical and 
electrocardiography examinations.
We excluded patients with pre-existing vascular 
complications from the study. Vascular complications 
were defined as ischemic heart disease (myocardial 
infarction or coronary sclerosis), ischemic cerebrovascular 
disease (ischemic stroke, transient ischemic attack, 
carotid artery stenosis/occlusion) and peripheral 
ar ter ial disease. Vascular complications were 
established by patient history or upon the results of 
imaging techniques. Any lesions with measurable 
intravascular stenosis were defined as clinically 
signif icant. Fur ther exclusion criter ia included 
previous and ongoing lipid lowering therapy, chronic 
inflammatory conditions, autoimmune disease, and 
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endocrine or active liver disease including type 1 
and 2 diabetes mellitus, chronic renal disease and 
malignancy.
Furthermore, thirty-two individuals were enrolled as a 
control population confirmed to be healthy by clinical 
and laboratory examinations.
Biochemical assays
After an overnight fasting period venous blood 
samples were taken into evacuated tubes and sera 
were prepared immediately by centrifugation at 
1,500 × g for 10 min at 4 °C. Multiple aliquots of 
each samples were separated and stored at -70 °C. 
Routine laboratory analyses: total cholesterol, 
HDL-C, LDL-cholesterol (LDL-C), C-reactive protein 
(CRP), triglyceride, ApoA1, apolipoprotein B (ApoB), 
lipoprotein(a), hemoglobin A1c (HbA1c), and super-
sensitive thyroid stimulating hormone were performed 
from fresh sera with Cobas c501 autoanalyzer (Roche 
Ltd., Mannheim, Germany) in the Department of 
Laboratory Medicine of University of Debrecen. Tests 
were performed according to the recommendation of 
the manufacturer. All the reagents were purchased 
from the same vendor.
Paraoxonase-1 activities and phenotype
PON1 paraoxonase activity was measured by a 
kinetic, semi-automated method. Briefly, paraoxon 
(O,O-diethyl-O-p-nitrophenyl-phosphate, Sigma, 
Hungary) was used as a substrate, and the generation 
of 4-nitrophenol was measured on a microtiter plate 
(Greiner Bio-One GmbH, Germany). The total of 
15 µL serum was mixed with 285 µL Tris-HCl buffer 
(100 mmol/L, pH = 8.0) containing 2 mmol/L CaCl2 and 
5.5 mmol/L paraoxon. The absorbance was monitored 
at 405 nm (25 °C), in every minute for 6 min by a 
Beckman Coulter DTX880 Plate Reader (Beckman 
Coulter, California, USA) equipped with multimode 
detector. Enzyme activity was calculated using the 
molar extinction coefficient 17,600 M-1cm-1. PON1 
paraoxonase activity is expressed as units per liter 
of serum, where 1 unit equals 1 µmol of substrate 
hydrolyzed per minute.
PON1 arylesterase activity was assayed by a standard 
containing 1 mmol/L phenylacetate substrate (Sigma, 
Hungary) in 20 mmol/L Tris-HCl, pH = 8.0. The 
reaction was started by adding the serum and the 
absorbance was monitored at 270 nm. Blanks were 
included to correct for the spontaneous hydrolysis 
of phenylacetate. We calculated the enzyme activity 
using the molar extinction coefficient 1,310 M-1cm-1. 
PON1 arylesterase activity is expressed in U/mL; 
1 U is defined as 1 μmol phenylacetate hydrolyzed 
per minute.
To calculate PON1 phenotype the dual substrate 
method was used[17]. The genetic polymorphism at 
codon 192 Q→R (Arg/Gln at position 192) has the 
most significant impact on the enzyme activity as 
hydrolysis of paraoxon is faster by the R allele than 
by the Q allele. The allozyme determined by the R 
allele was designated type B, while the allozyme 
identified by the Q allele was nominated type A. In 
contrast, both R and Q alleles had similar arylesterase 
activity. The ratio of the hydrolysis of paraoxon 
in the presence of 1 mol/L NaCl (salt-stimulated 
paraoxonase) to the hydrolysis of phenylacetate was 
used to assign individuals to one of the three possible 
PON1 phenotypes: AA (low activity), AB (intermediate 
activity) and BB (high activity). Cut-off values between 
phenotypes were as follows: ratio below 3.0 for AA, 
ratio between 3.0 and 7.0 for AB and ratio over 7.0 for 
BB phenotype.
Serum myeloperoxidase concentration 
measurement
Myeloperoxidase serum concentrat ions were 
measured by commercially available sandwich 
enzyme-linked immunosorbent assay (ELISA) kits 
(R&D Systems Europe Ltd., Abington, England). 
The ELISA assay was performed according to the 
manufacturer’s instructions. The intra- and inter-assay 
coefficient of variations was 6.5-9.4%.
HDL subfraction analysis
HDL subfract ions were determined using an 
electrophoretic method on polyacrylamide gel with 
the Lipoprint System (Quantimetrix Corp., CA, 
USA) according to manufacturer’s instructions. 
This commercially available system separates 
HDL subfractions from human serum on the basis 
of their size applying preloaded gel tubes for HDL 
determinations.
C onc i se ly,  25  μ L  se r um was  added  to  t he 
polyacrylamide gel tubes along with 300 μL loading 
gel solution. The tubes contained Sudan Black as 
a lipophilic dye and were photopolimerized at room 
temperature for 30 min. Electrophoresis with tubes 
containing sera samples and the manufacturer’s quality 
controls were performed at a constant of 3 mA/tube 
for 50 min. Subfraction bands were scanned with an 
ArtixScan M1 digital scanner (Microtek International 
Inc., CA, USA) and were identified by their mobility (Rf) 
using very-LDL (VLDL) + LDL as the starting (Rf 0.0) 
and albumin as the ending (Rf 1.0) reference point.
Ten HDL subfractions were differentiated between 
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serum level of CRP. Serum glucose and HbA1c levels 
were also significantly higher in patients, although 
they remained in the normal range. Mean age and 
body mass index of patients were also significantly 
higher compared to controls. Concentration of serum 
MPO was significantly higher in patients [Figure 2A]. 
We could not find significant differences in PON1 
paraoxonase and arylesterase activities between the 
two study groups. Large inter-individual variations 
in PON1 paraoxonase and arylesterase enzyme 
activities were found both in dyslipidemic patients and 
controls [Figure 2C and D]. The MPO/PON1 ratio was 
significantly higher in dyslipidemic patients compared 
to controls [Table 1 and Figure 2B].
Significant negative correlation was detected between 
PON1 arylesterase activity and the concentration of 
MPO (r = -0.38; P < 0.001) in the whole study group 
(data not shown). Analyzing these associations in the 
two groups separately, correlation remained significant 
only in patients (r = -0.38; P < 0.001). The PON1 
phenotype distribution was as follows: in the patient 
group 80.2 % (n = 65) were AA, 19.8 % (n = 16) were 
AB phenotype, and there were no patients with BB 
phenotype. The phenotype distribution (AA-AB) was 
87.5% (n = 28), 12.5% (n = 4) in controls, respectively. 
The allelic frequencies followed the Hardy-Weinberg 
equilibrium and no significant differences were found 
between the subgroups.
The absolute amounts and ratios of lipoprotein 
subfractions are shown on Table 2. Although HDL-C 
levels fell into the normal range in both studied groups, 
VLDL + LDL and albumin peaks, and were grouped 
into three major classes: large (from HDL1 to HDL3), 
intermediate (from HDL4 to HDL7) and small (HDL8 to 
HDL10) HDL subfractions. Cholesterol concentrations 
of the HDL particle subsets were calculated by 
multiplying the total cholesterol concentration of the 
samples by the relative area under the curve of the 
subfraction bands [Figure 1].
Statistical methods
Statistical analysis was performed by STATISTICA 
(ver 8.0; StatSoft Inc., Tulsa, OK, USA). We tested 
the normality of data distribution by Kolmogorov-
Smirnov test. Data are presented by descriptive 
analysis [mean ± SD in case of normal distribution, 
or median (lower quartile - upper quartile) in the case 
of non-normal distribution]. Comparisons between 
groups were performed by Student’s unpaired t-
test in case of normally distributed variables and by 
Mann-Whitney U-test in case of variables with non-
normal distribution. Correlations between continuous 
variables were assessed by linear regression analysis 
using Pearson’s test. Differences with P < 0.05 were 
considered to be statistically significant.
RESULTS
Signif icant ly higher total cholesterol,  LDL-C, 
triglyceride, lipoprotein(a), apo B and CRP levels 
were found in the untreated dyslipidemic patients 
compared to healthy controls. A few patients had higher 
CRP levels, however, we could not find significant 
correlations between the studied parameters and the 
Figure 1: HDL subfraction profile in a healthy subject determined using an electrophoretic method on polyacrylamide gel with the Lipoprint 
System. Ten HDL subfractions were differentiated between VLDL + LDL and albumin peaks, and were grouped into three major classes: 
large (from HDL1 to HDL3), intermediate (from HDL4 to HDL7) and small (HDL8 to HDL10) HDL subfractions. HDL: high-density lipoprotein; 
VLDL: very-low-density lipoprotein
Area %                 14     13 8 11  12    22     6   5    5                5
Large           Intermediate                Small
1      2  3   4   5      6      7   8    9               10
2/ 6/2013
13: 57
SAMPLE: 8-tube   8 hdl              Quantimetrix LIPOPRINT® SYSTEM
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differences between patients and controls [Table 2].
DISCUSSION
The measurement of serum levels of HDL-C has 
there was a shift toward the small-sized HDL particles 
in dyslipidemic patients compared to controls. The 
ratio of intermediate HDL subfraction was found to be 
significantly lower in dyslipidemic patients compared 
to controls, but there were no further significant 
Table 1: Laboratory parameters and anthropometric data of the patients and healthy controls
Dyslipidemic patients Healthy controls P
Number of patients 81 32
Age (years) 48.9 ± 14.3 41.8 ± 5.9 < 0.01
Female/male 49/32 19/13 NS
BMI (kg/m2) 28.1 ± 5.0 24.5 ± 2.5 < 0.01
Waist circumference (cm)
Females
Males
89.4 ± 13.2
101.7 ± 11.2
85.7 ± 6.6
92.75 ± 7.6
< 0.05
< 0.05
Glucose (mmol/L) 5.1 (4.8-5.5) 4.8 (4.6-5.1) < 0.01
HbA1C (%) 5.4 (5.2-5.9) 5.1 (4.8-5.3) < 0.01
Total cholesterol (mmol/L) 7.07 ± 1.69 5.07 ± 0.78 < 0.01
LDL-C (mmol/L) 4.52 ± 1.43 2.92 ± 0.51 < 0.01
HDL-C (mmol/L) 1.56 ± 0.54 1.55 ± 0.46 NS
Triglyceride (mmol/L) 1.6 (1.1-3.0) 1.2 (0.8-1.4) < 0.01
Lipoprotein(a) (mg/L) 191 (77-587) 70 (30-214) < 0.01
Apolipoprotein A1 (g/L) 1.71 ± 0.59 1.68 ± 0.31 NS
Apolipoprotein B (g/L) 1.33 ± 0.37 0.94 ± 0.18 < 0.01
hsCRP (mg/L) 2.4 (1.0-45.3) 2.0 (0.6-2.9) < 0.05
Thyroid stimulating hormone (mU/L) 2.1 ± 1.29 1.94 ± 1.1 NS
Myeloperoxidase (ng/mL) 869 (131-1,272) 205 (125-257) < 0.05
Paraoxonase activity (U/L) 98 (62-210) 83 (48-167) NS
Arylesterase activity (U/L) 132 (112-162) 127 (110-160) NS
Myeloperoxidase/paraoxonase (ug/U) 3.56 (1.28-16.03) 2.81 (0.89-4.03) < 0.05
Figure 2: Levels of serum MPO (A), MPO/PON1 ratio (B), activities of serum paraoxonase (C), and arylesterase (D) in dyslipidemic patients 
and controls. MPO: myeloperoxidase; PON1: paraoxonase-1
Data are presented as mean ± standard deviation or median (lower-upper quartiles). NS: non-significant; BMI: body mass index; HbA1c: 
hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; hsCRP: high sensitivity C-reactive 
protein
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not be crucial, at least in dyslipidemic patients without 
manifest vascular complications. It must be noted that 
there can be notable differences in data produced 
by different analytical techniques applied for HDL 
subclass analysis. Still, these data may shift the focus 
from HDL subfractions to HDL function.
Measurement of PON1 activity is an accepted 
indicator of the HDL antioxidant property and a 
promising biomarker of HDL function independently 
of HDL-C levels[20]. PON1 inhibits lipoprotein oxidation 
and macrophage foam cell formation. Moreover, it 
possesses homocysteine-thiolactonase activity and 
stimulates macrophage cholesterol efflux that may also 
be responsible for its anti-atherogenic properties[7]. A 
previous meta-analysis comprising 47 studies reported 
markedly lower PON1 activities in patients with 
coronary heart disease than in unaffected controls[21]. 
Decreased paraoxonase activities were found in 
a number of medical conditions including familial 
hypercholesterolemia and diabetes mellitus[7]. However, 
it is also well known that paraoxonase activities can 
vary by over 40-fold between individuals, in part 
because of its genetic polymorphisms[22,23]. Although 
many environmental and pharmaceutical modulators 
of PON1 are known, by far the biggest effect on 
PON1 activity levels is through these polymorphisms. 
The coding region PON1-Q192R polymorphism 
determines a substrate dependent effect on activity. 
Some substrates e.g. paraoxon are hydrolyzed faster 
by the R- isoform while others such as phenylacetate 
and diazoxon are hydrolyzed more rapidly by the Q- 
isoform[22]. Therefore using the dual substrate method 
the PON1-Q192R polymorphism can be evaluated. 
In the present study we could not find significant 
differences in PON1 paraoxonase and arylesterase 
activities between patients and controls, but we 
also observed the large inter-individual variations in 
enzyme activities. Therefore, we evaluated the PON1 
Q192R phenotype distribution and allelic frequencies. 
The allelic frequencies followed the Hardy-Weinberg 
been standardized and accepted in everyday clinical 
practice, but it fails to capture the complexity of 
HDL structure and function. Previous proteomic 
studies have revealed more than 100 proteins on 
HDL particles including structure proteins, enzymes, 
complement components and proteinase inhibitors. It 
became clear that the protective role of HDL against 
atherogenesis may relate to its composition as much 
as to its concentration in the plasma[18]. By contrast, 
there is no accepted gold standard to measure the 
physical and functional properties of HDL particles, 
although several tests and assays have been reported 
in the last few decades[1]. Consequently, results of the 
various studies are often not comparable, confusing 
and not applicable in clinical practice. Indeed, the 
assessment of HDL structure and functions has 
become a high priority novel target to investigate the 
association between HDL and cardiovascular risk. 
Therefore, any further data on parallel investigation of 
HDL subfractions and functional markers may improve 
our knowledge on this field.
Because of the various techniques used for HDL 
subfraction detection, it is not surpr ising that 
considerable controversy exists as to the clinical 
usefulness of HDL subfractions for the prediction of 
cardiovascular risk. Basically, HDL-C includes two 
major subfractions: lipid-enriched, larger HDL2, which 
has a major role in reverse cholesterol transport, 
and protein-enriched, smaller HDL3, whose anti-
atherogenic role is less clear, but is able to bind 
several antioxidant enzymes including PON1. Although 
the results of previous studies are not concordant, a 
higher ratio of the larger HDL2 particles may protective 
against atherogenesis, while the smaller subclasses 
are positively correlated with the risk of cardiovascular 
disease [19]. We found a shift towards the smaller 
HDL subfractions, which may be unfavorable for 
our dyslipidemic patients. On the other hand, most 
of these changes were not significant, therefore the 
importance of alterations in HDL subfractions might 
Table 2: Concentration and ratio of high-density lipoprotein subfractions in dyslipidemic patients and healthy 
controls
Dyslipidemic patients Healthy controls P
HDL subfraction concentrations (mmol/L)
   Large HDL 0.42 (0.27-0.67) 0.45 (0.31-0.61) NS
   Intermediate HDL 0.73 (0.59-0.87) 0.75 (0.66-0.85) NS
   Small HDL 0.34 (0.23-0.43) 0.28 (0.25-0.34) NS
HDL subfraction ratios (%)
   Large HDL 29.7 (21.5-35.4) 31.6 (24.4-34.6) NS
   Intermediate HDL 48.3 (45-51.4) 51.5 (48.3-54.3) < 0.05
   Small HDL 21.6 (16.4-26.6) 18.4 (15.5-22.5) NS
Values are presented as mean ± standard deviation or median (lower-upper quartiles). NS: non-significant; HDL: high-density lipoprotein
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correlations between the studied parameters and 
the age. Therefore, we concluded that age may not 
influence our results in this study. It must be noted 
that HDL subfraction ratios are derived secondary 
parameters that may include additional error based on 
method of calculation. Data on further HDL functional 
assays such as HDL cholesterol ef f lux assay, 
measurement of lecithin: cholesterol acyltransferase or 
platelet-activating factor-acetylhydrolase activity would 
add further information on HDL property.
In summary, we found altered HDL function in 
dyslipidemic patients, characterized by increased 
level of MPO and MPO/PON1, even in patients 
without clinically detectable symptoms of vascular 
complications. However, PON1 paraoxonase and 
arylesterase activities were unaltered. There was a 
shift towards the smaller HDL subfractions, but these 
changes were not significant; indicating that the 
importance of alterations in HDL subfractions might 
not be crucial in patients with dyslipidemia. Our results 
highlights the importance of HDL-associated pro- and 
antioxidant enzymes suggesting the possible clinical 
benefit of MPO/PON1 calculation and confirms that 
quantification of HDL-C level alone provides limited 
data regarding HDL’s cardioprotective effect. Further 
studies on larger patient populations are needed to 
identify and characterize the best markers of HDL 
functions.
Data on HDL structural and functional properties may 
improve the efficacy of cardiovascular risk prediction 
and development of novel anti-atherogenic treatment 
strategies in dyslipidemia.
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equilibrium and no significant differences were found 
between the subgroups. According to the results, 
because of the large inter-individual variability, PON1 
activity measurement alone might not became a 
useful biomarker for cardiovascular risk prediction in 
dyslipidemic patients without vascular complications.
MPO is a leukocyte-derived heme protein that binds 
to HDL. As a part of the innate immune host defense 
system, MPO uses hydrogen peroxide to generate 
an array of reactive oxidant and free radical species 
such as hypochlorous acid possessing antimicrobial 
effect. However, these reactive species can also foster 
oxidative injury to host molecules as well. Indeed, 
MPO catalyzes generation of nitrating oxidants and 
promotes both protein modifications and initiates lipid 
peroxidation leading to enhanced atherosclerosis[24]. 
Plasma, serum, and leukocyte MPO levels have been 
associated with coronary artery disease[25]; incident 
risk of myocardial infarction, death, and need for 
revascularization[26,27]. In a previous study we found 
signif icantly elevated MPO levels in overweight 
hyperlipidemic patients with or without cardiovascular 
complications[28]. In the present study we also found 
significantly higher MPO levels in dyslipidemic patients 
without any vascular complications compared to 
healthy subjects.
Interestingly, both PON1 and MPO interact at the 
same site on HDL, reciprocally modulate each 
other’s function, influencing the antioxidant and anti-
inflammatory function of HDL[11]. Our previous study 
on a similar patient population also highlighted the 
importance of this reciprocal inhibition[29]. Furthermore, 
a recent study showed that serum MPO/PON1 ratio 
may be a potential indicator of dysfunctional high-
density lipoprotein and risk stratification in coronary 
artery disease[30]. Therefore, MPO/PON1 ratio was 
also calculated and we found significantly higher MPO/
PON1 ratio in our dyslipidemic patients compared to 
controls indicating an increased risk for cardiovascular 
complications. Moreover, in line with the results of 
previous studies, significant negative correlation was 
found between myeloperoxidase levels and PON1 
arylesterase activities that demonstrates the reciprocal 
inhibit ion between these two HDL-associated 
enzymes. Hence, calculation of MPO/PON1 ratio may 
give information about the function of the enzyme 
complex and characterize HDL function.
Some limitations of the study must be noted. The 
power of the study may be reduced because of the 
relatively small size of the study population. Age 
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and controls, however, we could not find significant 
                                                                               Vessel Plus ¦ First Published on November 21, 2017
Harangi et al.                                                                                                                                                              HDL structure and function in dyslipidemia
8
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. 
A new hypothesis of the beneficial action of fibrates? Diabetes Metab 
2001;27:604-10.
15. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, 
Mikhailidis DP, Elisaf MS. The effects of ezetimibe and orlistat, alone 
or in combination, on high-density lipoprotein (HDL) subclasses and 
HDL-associated enzyme activities in overweight and obese patients 
with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-8.
16. Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in 
measuring HDL subfractions and human paraoxonase-1 activity during 
statin treatment. Cardiovasc Drugs Ther 2009;23:501-10.
17. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. 
Characteristics of the genetically determined allozymic forms of human 
serum paraoxonase/arylesterase. Drug Metab Dispos 1991;19:107-12.
18. Schaefer EJ, Anthanont P, Asztalos BF. High-density lipoprotein 
metabolism, composition, function, and deficiency. Curr Opin Lipidol 
2014;25:194-9.
19. Li JJ, Zhang Y, Li S, Cui CJ, Zhu CG, Guo YL, Wu NQ, Xu RX, Liu 
G, Dong Q, Sun J. Large HDL subfraction but not HDL-C is closely 
linked with risk factors, coronary severity and outcomes in a cohort of 
nontreated patients with stable coronary artery disease: a prospective 
observational study. Medicine (Baltimore) 2016;95:e2600.
20. Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. 
Front Pharmacol 2015;6:222.
21. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, Wu X. Quantitative 
assessment of the influence of paraoxonase 1 activity and coronary 
heart disease risk. DNA Cell Biol 2012;31:975-82.
22. Mackness B, Turkie W, Mackness M. Paraoxonase-1 (PON1) promoter 
region polymorphisms, serum PON1 status and coronary heart disease. 
Arch Med Sci 2013;9:8-13.
23. Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop IE, González-
Castro TB, Rodríguez-Pérez C, López-Narváez ML, Rodríguez-Pérez 
JM, Cámara-Álvarez JF. Effects of paraoxonase 1 gene polymorphisms 
on heart diseases: systematic review and meta-analysis of 64 case-
control studies. Medicine (Baltimore) 2016;95:e5298.
24. Zhou B, Zu L, Chen Y, Zheng X, Wang Y, Pan B, Dong M, Zhou E, 
Zhao M, Zhang Y, Zheng L, Gao W. Myeloperoxidase-oxidized high 
density lipoprotein impairs atherosclerotic plaque stability by inhibiting 
smooth muscle cell migration. Lipids Health Dis 2017;16:3.
25. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The 
roles of myeloperoxidase in coronary artery disease and its potential 
implication in plaque rupture. Redox Rep 2017;22:51-73.
26. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, 
Simoons ML, Hamm CW; CAPTURE Investigators. Myeloperoxidase 
serum levels predict risk in patients with acute coronary syndromes. 
Circulation 2003;108:1440-5.
27. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles 
RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, 
Hazen SL. Prognostic value of myeloperoxidase in patients with chest 
pain. N Engl J Med 2003;349:1595-604.
28. Szentpéteri A, Zsíros N, Varga VE, Lőrincz H, Katkó M, Seres I, Fülöp 
P, Paragh G, Harangi M. Paraoxonase-1 and myeloperoxidase correlate 
with vascular biomarkers in overweight patients with newly diagnosed 
untreated hyperlipidaemia. Vasa 2017;46:370-6.
29. Zsíros N, Koncsos P, Lőrincz H, Seres I, Katkó M, Szentpéteri A, 
Varga VE, Fülöp P, Paragh G, Harangi M. Paraoxonase-1 arylesterase 
activity is an independent predictor of myeloperoxidase levels in 
overweight patients with or without cardiovascular complications. Clin 
Biochem 2016;49:862-7.
30. Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori 
K, Miyamoto-Sasaki M, Shinohara M, Nishimura K, Ishida T, Hirata 
K. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of 
dysfunctional high-density lipoprotein and risk stratification in coronary 
artery disease. Atherosclerosis 2014;234:288-94.
Conflicts of interest
There are no conflicts of interest.
Patient consent
Informed consent was obtained from all patients after 
approval of the local ethics committee.
Ethics approval
The study was approved by local and regional ethics 
committees.
REFERENCES
1. Hafiane A, Genest J. High density lipoproteins: Measurement 
techniques and potential biomarkers of cardiovascular risk. BBA Clin 
2015;3:175-88.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen 
M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study 
Investigators. Effect of potentially modifiable risk factors associated 
with myocardial infarction in 52 countries (the INTERHEART study): 
case-control study. Lancet 2004;364:937-52.
3. Ramirez A, Hu PP. Low high-density lipoprotein and risk of 
myocardial infarction. Clin Med Insights Cardiol 2015;9:113-7.
4. Annema W, von Eckardstein A. Dysfunctional high-density 
lipoproteins in coronary heart disease: implications for diagnostics and 
therapy. Transl Res 2016;173:30-57.
5. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, 
Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, 
Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang 
S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, 
Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional 
apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203.
6. Khine HW, Teiber JF, Haley RW, Khera A, Ayers CR, Rohatgi A. 
Association of the serum myeloperoxidase/high-density lipoprotein 
particle ratio and incident cardiovascular events in a multi-ethnic 
population: observations from the dallas heart study. Atherosclerosis 
2017;263:156-62.
7. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene 
structure and expression, promiscuous activities and multiple 
physiological roles. Gene 2015;567:12-21.
8. Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine 
metabolism. Amino Acids 2012;43:1405-17.
9. Ben-David M, Elias M, Filippi JJ, Duñach E, Silman I, Sussman JL, 
Tawfik DS. Catalytic versatility and backups in enzyme active sites: 
the case of serum paraoxonase 1. J Mol Biol 2012;418:181-96.
10. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim 
Acta 2015;439:5-13.
11. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, 
Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato 
AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, 
Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. 
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary 
complex. J Clin Invest 2013;123:3815-28.
12. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, 
Derdák Z, Illyés L, Paragh G. Atorvastatin effect on the distribution of 
high-density lipoprotein subfractions and human paraoxonase activity. 
Transl Res 2009;153:190-8.
13. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on 
paraoxonase-1 status: A systematic review and meta-analysis of 25 
clinical trials. Prog Lipid Res 2015;60:50-73.
14. Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. 
